Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and genetic insights into novel TP53 mutations in De Novo AML patients.

Clinical and experimental medicine - 12 Feb 2026

Akram Afia Muhammad, Hayat Sikandar, Yousaf Hassan, Sarwar Noreen, Tahir Asma, Ali Sakina, Yaqoob Fatima, Zafar Amjad, Hassan Hesham M, Dabiellil Mutwakel, Khan Malik Ihsan Ullah

Abstract excerpt

This study intended to uncover any potential variations in TP53 gene particularly the exons 3–7 as this region is reported to have abundant oncogenic variations with adverse impacts on its structural stability and functional activities. The selected region of TP53 was amplified in ninety de novo AML patients and amplicons were Sanger sequenced to analyze possible nucleotide variations. Ten (10) mutations were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Computational Biology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Sequence Analysis, DNA

Share to Survival Analysis

Share to Tumor Suppressor Protein p53

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 41677935
DOI: 10.1007/s10238-026-02079-6
PMCID: PMC12909321

Genes

TP53
EFS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and genetic insights into novel TP53 mutations in De Novo AML patients.PMID 41677935Read ↗

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?Semantic proximity Read ↗

<i>TP53</i> mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomesSemantic proximity Read ↗

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation.Semantic proximity Read ↗

Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms.Semantic proximity Read ↗

TP53 in AML and MDS: The new (old) kid on the block.Semantic proximity Read ↗

Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting.Semantic proximity Read ↗

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read ↗

TP53 in MDS and AML: Biological and clinical advances.Semantic proximity Read ↗

Clinical and Molecular Characterization of p53-Mutated Acute Myeloid LeukemiaSemantic proximity Read ↗

[Clinical and prognostic values of TP53 mutation in patients with acute myeloid leukemia].Semantic proximity Read ↗

[Advances in the Treatment of Acute Myeloid Leukemia with TP53 Mutations-Review].Semantic proximity Read ↗

Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.